SCHEMBL2537236

SCHEMBL2537236

COc1cc(=O)[nH]c2ccc(Cl)cc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
AR P10275 1/20 0.56
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
RXFP1 Q9HBX9 1/20 0.54
TP53 P04637 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
IGF1R P08069 1/20 0.51
CYP1A2 P05177 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
MAP2 P11137 1/20 0.47
TUBB4A P04350 3/20 0.47
TUBB P07437 3/20 0.47
TUBA3C P0DPH7 3/20 0.47
TUBA1B P68363 3/20 0.47
TUBA4A P68366 3/20 0.47
TUBB4B P68371 3/20 0.47
TUBB3 Q13509 3/20 0.47
TUBB2A Q13885 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12533056 0.81 AR (0.57) LMNAARKMT2AMEN1SMN1; SMN2
SCHEMBL1771739 0.80 AR (0.56) LMNAARGAATUBB4ATUBB
SCHEMBL3151814 0.79 LMNA (1.00) LMNAARKMT2AMEN1RXFP1
SCHEMBL3217241 0.78 MEN1 (0.60) LMNAKMT2AMEN1RXFP1TP53
SCHEMBL2799080 0.77 TNKS2 (0.61) ARKMT2AMEN1SMN1; SMN2IGF1R
SCHEMBL31664571 0.77 TNKS2 (0.61) ARKMT2AMEN1SMN1; SMN2IGF1R
SCHEMBL31664560 0.77 KDM4E (0.59) LMNAARKMT2AMEN1TP53
SCHEMBL30175823 0.76 MEN1 (0.69) LMNAKMT2AMEN1RXFP1TP53
SCHEMBL31254142 0.75 CTSV (0.60) LMNAARKMT2AMEN1TUBB4A
SCHEMBL25904276 0.75 LMNA (0.47) LMNAKMT2AMEN1RXFP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-8044068-B2 Aminopyrrolidine compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-10-25 US disclosed
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-11-26 US disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed
EP-2003131-A1 AMINOPYRROLIDINE COMPOUND Taisho Pharmaceutical Co. Ltd. (JP) 2008-12-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291940-A1 AMINOPYRROLIDINE COMPOUND MC4R, MC5R, MC2R LMNA 4408/4885AR 162/4885KMT2A 914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.